These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 9137526

  • 1. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines.
    Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T.
    Cancer Chemother Pharmacol; 1997; 40(1):31-7. PubMed ID: 9137526
    [Abstract] [Full Text] [Related]

  • 2. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines.
    Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T.
    Clin Cancer Res; 1996 Feb; 2(2):427-32. PubMed ID: 9816187
    [Abstract] [Full Text] [Related]

  • 3. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer.
    Arnold NB, Ketterer K, Kleeff J, Friess H, Büchler MW, Korc M.
    Cancer Res; 2004 May 15; 64(10):3599-606. PubMed ID: 15150118
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F, Meng L, Zhou J, Xing H, Wang S, Xu G, Zhu H, Wang B, Chen G, Lu YP, Ma D.
    Biochem Biophys Res Commun; 2005 Oct 07; 335(4):1070-7. PubMed ID: 16105650
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Secretion of thioredoxin enhances cellular resistance to cis-diamminedichloroplatinum (II).
    Sasada T, Nakamura H, Ueda S, Iwata S, Ueno M, Takabayashi A, Yodoi J.
    Antioxid Redox Signal; 2000 Oct 07; 2(4):695-705. PubMed ID: 11213475
    [Abstract] [Full Text] [Related]

  • 13. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 14. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity.
    Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama A, Taniguchi Y, Takabayashi A, Yodoi J.
    J Clin Invest; 1996 May 15; 97(10):2268-76. PubMed ID: 8636406
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.
    Chan MM, Soprano KJ, Weinstein K, Fong D.
    J Cell Physiol; 2006 May 15; 207(2):389-96. PubMed ID: 16402374
    [Abstract] [Full Text] [Related]

  • 20. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide.
    Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, Niitsu Y.
    Cancer Res; 1996 Aug 01; 56(15):3577-82. PubMed ID: 8758929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.